Aklief is manufactured by Galderma [1]. Galderma is a global dermatology company with a focus on developing and marketing innovative treatments for skin conditions [2].
What is Aklief used for?
Aklief is a topical retinoid cream approved for the treatment of acne vulgaris in patients 12 years of age and older [3]. It is applied once daily to the face and/or trunk [3].
How does Aklief work?
Aklief's active ingredient is trifarotene, a molecule that selectively targets specific retinoic acid receptors (RARs) in the skin [4]. By targeting these receptors, trifarotene helps to normalize the shedding of skin cells within hair follicles, reduce inflammation, and inhibit the growth of Cutibacterium acnes (formerly Propionibacterium acnes), all of which are key factors in the development of acne [4][5].
When does Aklief's patent protection expire?
Patent information for Aklief, including expiry dates, can be accessed through resources like DrugPatentWatch.com [6].
What are the potential side effects of Aklief?
Common side effects of Aklief include application site irritation, dryness, redness, peeling, and burning [3]. These reactions are typical for topical retinoids and often subside as treatment continues [4]. Severe or persistent irritation should be reported to a healthcare provider [3].
How does Aklief compare to other acne treatments?
Aklief offers a selective retinoic acid receptor-gamma (RAR-γ) agonist mechanism, which may differentiate it from other topical retinoids. This selective action is designed to target specific pathways involved in acne formation with potentially improved tolerability [4][5]. However, like other retinoids, it requires consistent application and may cause initial skin irritation [4].
What are the regulatory approvals for Aklief?
Aklief has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for the treatment of acne vulgaris [3]. It is also approved in other regions, including Europe [4].
What clinical data supports Aklief's efficacy?
Clinical trials have demonstrated that Aklief is effective in reducing inflammatory and non-inflammatory acne lesions. For example, studies have shown significant reductions in lesion counts with once-daily application [4][5].
---
Sources:
[1] https://www.galderma.com/
[2] https://www.galderma.com/our-science/our-products/aklieftm/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213760s000lbl.pdf
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393904/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039593/
[6] https://drugpatentwatch.com/